Table 1 Demographic data of subjects recruited in this study
Characteristics | Active SLE Group | Inactive SLE Group | Psoriasis Group | Control Group |
|---|---|---|---|---|
Numbers | 13 | 16 | 5 | 10 |
Sex, female:male | 12:1 | 16:0 | 3:2 | 10:0 |
Age, years | 15 to 50 | 17 to 50 | 39 to 61 | 24 to 28 |
(mean ± S.D.) | (34.62 ± 11.46) | (33 ± 11.16) | (51 ± 9.88) | (25.6 ± 1.58) |
SLEDAI score | ≥ 6 | < 6 | - | - |
(mean ± S.D.) | (12.92 ± 7.83) | (2.56 ± 2.03) |  |  |
Range of PASI score | Â | Â | 11.2 to 27 | Â |
(mean ± S.D.) | - | - | (18.02 ± 5.38) | - |
Treatment (mg/day) | Â | Â | Â | Â |
(mean ± S.D.) |  |  |  |  |
   Prednisolone | 13.13 ± 10.06 | 9.38 ± 8.45 | - | - |
   Cyclophosphamide | - | 25 | - | - |
   Azathioprine | 50 ± 30.62 | 47.5 ± 33.54 | - | - |
   Mycophenolate mofetil | 1,250 | - | - | - |
   Methotrexate | - | - | 6.43 |  |